BioNTech Begins HIV Vaccine Trial as Six Cancer Data Readouts Loom

BioNTech begins HIV vaccine trial BNT168, but stock focus remains on oncology data readouts in 2026. Q1 revenue €118.1M, net loss €531.9M, cash €16.8B.

BioNTech has taken a step into one of medicine’s toughest challenges, launching a Phase I/II trial of its HIV vaccine candidate BNT168 in July 2026. The move underscores the breadth of the company’s mRNA platform, though investors are keeping their focus firmly on the oncology pipeline that will determine the stock’s direction over the coming months.

The HIV study, registered under NCT07698600, will enroll 126 participants aged 18 to 50 across two arms. Three cohorts consist of HIV-negative individuals receiving three doses of BNT168; two further cohorts involve HIV-positive patients on stable antiretroviral therapy who will receive four injections. Strict inclusion criteria require a viral load below 50 copies per milliliter for at least six months and a CD4 cell count of at least 500 per microliter at screening. The trial’s central feature is a controlled, temporary interruption of standard therapy to test whether the vaccine-induced immune response can suppress the virus on its own. Unlike traditional vaccine studies that measure viral load reduction, the primary endpoint here is the durability of suppression, reflecting the regulatory requirements for a functional cure. Early results are not expected until the study concludes in January 2028.

That timeline explains why the HIV programme is a long-term bet, not a near-term catalyst. What will drive the stock in 2026 is a slate of oncology data readouts that the company has trimmed from seven to six after a guidance cut earlier this year between January and May. None of these six planned milestones have reported results yet, leaving the shares in a waiting pattern. The most closely watched candidates are Pumitamig, a bispecific antibody, and various antibody-drug conjugate combinations, with later-stage registrational studies already underway.

Financially, BioNTech’s first quarter of 2026 showed revenue of €118.1 million, a net loss of €531.9 million, and a cash and securities pile of €16.8 billion. Management reaffirmed its full-year revenue forecast of €2.0 billion to €2.3 billion. The ample cash reserve provides a multi-year funding runway for the oncology pipeline without near-term dilution risk, but the substantial net loss underscores how capital-intensive the transition from a COVID vaccine franchise to a cancer drug developer remains.

Optimists point to the scale of the programme: BioNTech has more than doubled its number of Phase 2 and Phase 3 oncology studies in two years, with over 25 now running. Cost-cutting measures, including plans to consolidate manufacturing sites and achieve annual savings of roughly €500 million by 2029, alongside a share buyback programme of up to $1 billion, add support. If even a portion of the 2026 readouts – particularly the Pumitamig combinations – show clear efficacy signals, the stock could challenge the consensus analyst target of €107.07, a 32.8% premium to current levels.

Skeptics focus on execution risk. The guidance has already been trimmed, and the net loss of over half a billion euros in one quarter highlights how much capital the oncology pipeline consumes relative to a revenue base that remains thin. The COVID business continues to mature and shrink, adding a headwind. Furthermore, the company’s co-founders plan to spin out a separate mRNA-focused venture later in 2026, which some analysts view as a potential distraction at a moment when the oncology pipeline demands disciplined follow-through. An important nuance is that many of the 2026 data readouts are signal-finding rather than registrational, meaning a single positive or negative result is unlikely to determine the entire outlook.

On the technical side, the stock recently traded at €81.35, not far from its 50-day moving average of €79.26 but roughly 5% below the 200-day average of €84.86. The relative strength index stands at 50.9, indicating neutral territory. Over the past 12 months, the shares have fallen 12.76%, and they remain about 23% below the 52-week high of €105.80 reached in January.

The coming months will hinge on whether the six second-half 2026 oncology readouts confirm the antitumor activity seen in earlier Phase 2 signals. A clean run of positive late-stage data could push the stock back toward the 200-day moving average and beyond, with the €107.07 consensus target as the next major hurdle. Should the readouts disappoint or signal further delays, a retest of the March low of €68.35 is a distinct possibility. For now, the market is watching and waiting – the HIV vaccine is an intriguing scientific story, but it is the cancer data that will write the next chapter of BioNTech’s share price.